Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT04335682 | Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide(ARACOG) | completed | Phase 2 | 111 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04053842 | Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy(IGPC-5) | completed | Phase 2 | 16 | Glenn BaumanOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03543189 | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | completed | Phase 1 / Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05670106 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03042468 | Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC | completed | Phase 1 / Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01807065 | Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer | completed | Phase 2 | 51 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03315754 | Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. | completed | Phase 2 | 50 | Steba Biotech S.A.OTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04558866 | Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)(ExBAT) | completed | Phase 2 | 51 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06395753 | A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer | completed | Phase 2 | 55 | Debiopharm International SAINDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT06907641 | Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy(Co-PSMA) | completed | Phase 2 | 50 | St Vincent's Hospital, SydneyOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05478239 | ArtemiCoffee in Patients With Rising PSA | completed | Phase 2 | 20 | Zin W MyintOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03606837 | 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging(PROSTATEP) | completed | Phase 2 | 14 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03796767 | Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer(SOAR) | completed | Phase 2 | 20 | University of UtahOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04743934 | Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer(RAD 2003) | completed | Phase 2 | 44 | Andrew McDonaldOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03716739 | Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency | completed | Phase 2 | 136 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04037254 | Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring | completed | Phase 1 / Phase 2 | 22 | NRG OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT07209865 | 68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI | completed | Phase 2 | 82 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05171387 | Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer | completed | Phase 2 | 78 | BayerINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT01251861 | Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 2 | Jun 25, 2026 | clinicaltrials |
| NCT02217709 | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | completed | Phase 2 | 26 | University of Southern CaliforniaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04530552 | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03263650 | Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04751929 | Abemaciclib With or Without Atezolizumab for mCRPC | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03652493 | Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway(PRO-CARBO) | completed | Phase 2 | 16 | Centre Francois BaclesseOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05730712 | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 7 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT01171898 | Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 127 | Aragon Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06434909 | CYTALUX™for the Intraoperative Imaging of Prostate Cancer | completed | Phase 2 | 9 | Indiana UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03570827 | Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy | completed | Phase 2 | 53 | Mayo ClinicOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03934840 | CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone | completed | Phase 2 | 61 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03910660 | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. | completed | Phase 1 / Phase 2 | 98 | BioXcel Therapeutics IncINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT04019964 | Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | completed | Phase 2 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03604757 | 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks(UROPET) | completed | Phase 2 | 22 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04731844 | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | completed | Phase 2 | 30 | University of RochesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05114746 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan | completed | Phase 2 | 94 | Novartis PharmaceuticalsINDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07568444 | Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3) | completed | Phase 2 | 120 | University of Southern CaliforniaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05005728 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | Xencor, Inc.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT02649855 | Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05133440 | A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04925648 | Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction(PICASSO) | completed | Phase 2 | 4 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04523207 | A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases | completed | Phase 2 | 108 | Janssen Research & Development, LLCINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT01902680 | Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.(CURIEFOCALE) | completed | Phase 2 | 18 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02225704 | Radium-223 in Combination With Enzalutamide | completed | Phase 2 | 45 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02772588 | AASUR in High Risk Prostate Cancer | completed | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03496805 | Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy | completed | Phase 2 | 106 | Wake Forest University Health SciencesOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT00160979 | Transrectal Tumour Oxygen - US Army | completed | Phase 2 | 186 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05008900 | Timing of Post-prostatectomy PSMA Imaging(TOPP) | completed | Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials